How Weight Affects Migraine Disease
You are currently watching a preview of this interview. Unlock the full version by upgrading to an Access Pass bundle! Get FREE access to 8 expert interviews from Day 1 and Day 2 when you register today!
Key Questions
- Can significant weight gain trigger the onset of migraine?
- Is there a definitive causative relationship between weight and migraine, or is it simply middle age in which both weight and migraine increase?
- Is the risk of migraine any different for people who are overweight or underweight?
- Is there a correlation with being overweight or underweight and having chronic migraine?
- What does the research say about why many migraine symptoms are related to digestion?
- Does inflammation play a role in migraine?
- What are some practical ways to reduce weight safely for someone with migraine?
- Are there any weight loss tactics that can actually make migraine worse?
- Does research indicate that behavioral weight loss intervention or migraine education can reduce migraine frequency or severity?
- Do researchers know how reducing inflammation might affect migraine, and are anti-inflammatory supplements like turmeric, omega-3, or capsaicin considered effective for people with migraine?
- Are there any important considerations for how someone with migraine approaches exercise for weight loss?
Interview Notes
Dale Bond, PhD
Professor of Psychiatry & Human Behavior (Research)
The Miriam Hospital and Brown Alpert Medical School Weight Control and Diabetes Research Center
Dr. Dale Bond is a professor of psychiatry and human behavior at The Miriam Hospital and the Brown Alpert Medical School. He received M.S. and Ph.D. degrees in health promotion and education at Purdue University and the University of Utah, respectively, and completed postdoctoral training in behavioral medicine at Brown Alpert Medical School. His research involves two principal areas: (1) assessing and intervening on energy balance behaviors and related mechanisms in the context of bariatric surgery and obesity; and (2) assessment and treatment of psychological and behavioral risk factors and comorbidities among individuals who have migraine.
Dr. Bond has been awarded grants from the National Institute of Health (NIH) and other organizations to conduct prospective studies and randomized trials pursuant to advancement of these areas. He has received scientific honors/awards from the Association of Migraine Disorders and the American Society of Metabolic and Bariatric Surgery. He also sits on the editorial boards for multiple obesity-related journals, is a member of several committees for the American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), was a recent member of the NIH Behavioral Interventions and Outcomes study section, and is a research mentor within the NHLBI T32 Postdoctoral Training in Cardiovascular Behavioral Medicine Program at The Miriam Hospital and Brown University.
Interviews from Dale Bond, PhD
Purchase full access to the entire 2024 Summit. Includes:
- All expert interviews with separate audio (MP3) files & transcripts
- Lifetime on-demand access with no annual fee to 2024 Summit
- Interview Summaries
- Treatment Guidelines
- And much more!
Related Talks for: Day 3 (2021)
Preventing Attacks Before They Happen
Jan Lewis Brandes, MD
Light Sensitivity and Therapy for Migraine
Deborah Friedman, MD, MPH, FAAN, FAHS
How to Manage Weather Triggers
Jan Hoffmann, MD, PhD
Over the past 50 years, our mission at the National Headache Foundation has been to further awareness of headache and migraine as legitimate neurobiological diseases. Much has changed during this time. With aid from advanced technology and clinical innovation, there are more treatment options than ever before. However, we understand that these diseases are still largely misunderstood and that finding the right treatment options for you requires insight.
Impel NeuroPharma, Inc. is a late-stage biopharmaceutical company focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. Impel NeuroPharma is the first company to investigate targeting the upper nasal space with optimized therapeutic molecules and formulations for treating CNS diseases.
The Summit Co-Host and Producer, Paula is an alumni speaker who is a former business executive with chronic migraine, now thriving as a leading health advocate and editor.
